Prospects for the development of adjuvant therapy for non-small cell lung cancer
The standard approach for stage IB and IIIIIA non-small cell lung cancer (NSCLC), associated with the high risk of relapse, after total lung resection is adjuvant chemotherapy, nowadays. The 5-year survival benefit for this approach is about 5%, and the risk of relapse reduces from 11 to 15%, depend...
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | article |
| Langue: | RU |
| Publié: |
IP Habib O.N.
2020
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/0ce8e5769b2f4663b26654a8a7d6d7e7 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Soyez le premier à ajouter un commentaire!